Induction of oral tolerance to prevent diabetes with transgenic plants requires glutamic acid decarboxylase (GAD) and IL-4.
about
Viral and murine interleukin-10 are correctly processed and retain their biological activity when produced in tobacco.A novel expression platform for the production of diabetes-associated autoantigen human glutamic acid decarboxylase (hGAD65).Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes.Transgenic rice for allergy immunotherapyMucosal tolerance to prevent type 1 diabetes: can the outcome be improved in humans?Antigen-specific therapeutic approaches in Type 1 diabetesOral Administration of Silkworm-Produced GAD65 and Insulin Bi-Autoantigens against Type 1 DiabetesTransgenic plants in the biopharmaceutical market.Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice.Plant-made vaccines: biotechnology and immunology in animal health.Heat-shock protein 60 as a tool for novel therapeutic strategies that target the induction of regulatory T cells in human arthritis.Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.Immune Tolerance for Autoimmune Disease and Cell TransplantationInhibition of Th17 cells regulates autoimmune diabetes in NOD mice.CD103 is dispensable for anti-viral immunity and autoimmunity in a mouse model of virally-induced autoimmune diabetes.Comparative analysis of different biofactories for the production of a major diabetes autoantigen.Plant-based vaccines for oral delivery of type 1 diabetes-related autoantigens: Evaluating oral tolerance mechanisms and disease prevention in NOD mice.Comparative evaluation of recombinant protein production in different biofactories: the green perspective.In planta production of plant-derived and non-plant-derived adjuvants.Chloroplasts as expression platforms for plant-produced vaccines.Plant-made pharmaceuticals for the prevention and treatment of autoimmune diseases: where are we?T-cell autoantigens in the non-obese diabetic mouse model of autoimmune diabetes.Non-food/feed seeds as biofactories for the high-yield production of recombinant pharmaceuticals.Recombinant protein yield in rice seed is enhanced by specific suppression of endogenous seed proteins at the same deposit site.Human gastric epithelium produces IL-4 and IL-4delta2 isoform only upon Helicobacter pylori infection.Plant-based oral delivery of β-glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease.Taking a leaf from the book of oral tolerance.A fusion protein derived from plants holds promising potential as a new oral therapy for type 2 diabetes.High-yield expression of recombinant soybean agglutinin in plants using transient and stable systems.AEB-071 has minimal impact on onset of autoimmune diabetes in NOD mice.Production of biologically active human interleukin-4 in transgenic tobacco and potato.Therapeutic effectiveness of orally administered transgenic low-alkaloid tobacco expressing human interleukin-10 in a mouse model of colitis
P2860
Q21256644-5DF47937-AED5-4C67-97FA-FCCBC2E265B0Q33385000-74586824-06CC-406D-8DCA-E200FCC2D9D4Q33636716-38632C1D-23CC-4F88-8D86-C0586B92086AQ34161259-08574007-F50E-4962-94C9-8C292FFEE626Q35612665-3090F570-50A4-444D-97A9-D5F038F5FF74Q35762883-AD0FB63D-750C-4DB4-9BA0-AD019E5E92EDQ35897441-C629DE93-856A-458C-AAD9-00568505A86AQ36066053-A0D1DF41-C078-4467-A63D-A93CB4574981Q36083396-E0FE62E5-5A2A-4646-888F-3B2CC60DAC94Q36439033-E8AE7171-4FBE-4BCB-BF3C-97FF341B59FEQ36480993-CFCC2F20-6D34-4B05-9514-DBD67A83B559Q36640081-613C97D7-5BAC-4675-BECF-ED15B2230D05Q37099107-366FB5CC-2904-402D-A91B-09C9EAE38041Q37193763-A4D055C2-DAB9-45F0-9206-4F4F152F839FQ37251556-7314BA5D-C3B8-48CD-9E3F-F75D08D761D9Q37634156-1C99D890-EF46-405A-833A-47D48947067DQ37638227-31ECC25E-5E03-424C-87CB-69434FB2A209Q37679720-B91F03F3-464D-4B83-8359-47C06362DAD0Q37776716-92188081-D4E3-4609-8820-9F5D5A3DFE70Q37776719-0C8AE733-AC7C-462B-ADAC-7AE91203FDC6Q37776723-15C1C3D7-6CD3-472D-AC71-F69CF09E7201Q37805563-CF0A72D7-F2ED-4DF4-869C-E61FFF6CD118Q39560841-7C1A1934-D5C5-40E6-9F2A-E47033CA5850Q39571255-68CC0D3D-1806-45A9-A936-BE0E258882DCQ40027763-62028AEA-53B8-4701-95AE-36AA94AAB0DDQ41365905-0FE00C25-A5AD-42EE-A10D-DA2536ABC1D7Q41849649-153CD687-80F1-40BC-928C-F866B0800CA4Q43499161-644D35B8-E6C2-4C8F-A9E7-6486D4007DE6Q50574557-B3DB0831-1221-4346-A0C9-8C64D562E0F9Q51757895-46618FE1-5EBF-4E2C-A2ED-D65F6108DCEAQ53751033-0F287C15-6C64-4082-9374-92903F77BD1BQ58917333-F8948B6E-3CD7-45BA-A7D8-B88B66B058E4
P2860
Induction of oral tolerance to prevent diabetes with transgenic plants requires glutamic acid decarboxylase (GAD) and IL-4.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 March 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Induction of oral tolerance to ...... decarboxylase (GAD) and IL-4.
@en
Induction of oral tolerance to ...... es glutamic acid decarboxylase
@nl
type
label
Induction of oral tolerance to ...... decarboxylase (GAD) and IL-4.
@en
Induction of oral tolerance to ...... es glutamic acid decarboxylase
@nl
prefLabel
Induction of oral tolerance to ...... decarboxylase (GAD) and IL-4.
@en
Induction of oral tolerance to ...... es glutamic acid decarboxylase
@nl
P2093
P2860
P356
P1476
Induction of oral tolerance to ...... decarboxylase (GAD) and IL-4.
@en
P2093
Anthony M Jevnikar
James E Brandle
Shengwu Ma
P2860
P304
P356
10.1073/PNAS.0307420101
P407
P50
P577
2004-03-31T00:00:00Z